Originally published May 25.

Pharmacy-benefits manager Medco is planning to expand its pharmacogenetic test offerings and a suit of genomic services to all of its clients beginning in July.

The PBM, which provides services to 60 million people, began offering PGx testing two years ago to a limited number of its clients, offering tests for the anticoagulant warfarin and the breast cancer drug tamoxifen. Eventually, Medco rolled out its PGx testing program to around 200 clients representing 7 million lives.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.